Tumor markers in clinical practice: a review focusing on common solid cancers
about
Blood CEA levels for detecting recurrent colorectal cancerBlood CEA levels for detecting recurrent colorectal cancerBiosensors Incorporating Bimetallic Nanoparticles.Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.Simple patterned nanofiber scaffolds and its enhanced performance in immunoassay.Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancerKLHL21, a novel gene that contributes to the progression of hepatocellular carcinomaTransferrin-bound proteins as potential biomarkers for advanced breast cancer patients.Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay.The clinical significance of anti-mitotic spindle apparatus antibody (MSA) and anti-centromere antibody (ACA) detected in patients with small cell lung cancer (SCLC).The war on cancer: are we winning?Sperm parameters: paradigmatic index of good health and longevity.Precision treatment for cancer: role of prognostic and predictive markers.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Lanthanide-doped luminescent nano-bioprobes for the detection of tumor markers.The need for effective pancreatic cancer detection and management: a biomarker-based strategy.Extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without malignancy: a case reportReference Intervals of Alpha-Fetoprotein and Carcinoembryonic Antigen in the Apparently Healthy Population.The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.Limitations in the Use of Serum Epidermal Growth Factor Receptor Mutations as Prognostic Markers for Non-Small-Cell Lung Cancer.Coexistence of perineural invasion and lymph node metastases is a poor prognostic factor in patients with locally advanced rectal cancer after preoperative chemoradiotherapy followed by radical resection and adjuvant chemotherapyPersonalised treatment for cancer: role of biomarkers.Tumor-derived exosomes in ovarian cancer - liquid biopsies for early detection and real-time monitoring of cancer progression.Reference intervals of carbohydrate antigen 19-9 in the apparently healthy adult population.Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies.Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers.Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?Impact of plasma fibrinogen levels in benign and malignant soft tissue tumors.Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer.Effects on the tumor specific growth factor and tumor necrosis factor α in rats' precancerous lesion of primary hepatocellular carcinoma by direct moxibustion at Ganshu (BL 18) acupoint.Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series.Diminution of falsely elevated tumour markers following immunosuppression for systemic lupus erythematosus with neurological involvement.Quantitative Lateral Flow Immunoassay for Total Prostate Specific Antigen in SerumMolecular Diagnostics in Clinical OncologyPost-operative AICS status in completely resected lung cancer patients with pre-operative AICS abnormalities: predictive significance of disease recurrence
P2860
Q24186921-AFCCB9A0-9300-40DD-AB32-09FA18E4814AQ24194206-89A900FB-A41A-48EC-8939-A497B112647DQ29248731-C67D049E-4D6C-4813-A9D8-41B2D0FC7248Q33556583-6F433E9D-2729-4CC7-AA19-3EC65BA4E9D4Q35067899-3A901736-C124-4052-96C9-3EE231FA0BB6Q36061986-BDD47EBC-7498-40C1-B4D9-E5290F465ED8Q36171505-4998D192-CC9D-48B3-A98F-DBF105CC3E92Q36250711-2149E76E-29B3-4F4B-83AE-817ABCEBAFFDQ37351804-9082BA23-4F31-493E-8AF6-6F47526B6E46Q37692214-1599F569-EB07-4030-B7AE-125E3248CC98Q38097382-9A39DD57-23FF-4395-92FC-9C10496F6B43Q38139822-19B2199A-4974-4B01-A707-38A4ABF11972Q38179024-45102A1B-096F-401B-A564-F0783CA03A35Q38184632-CC2D75F2-674A-4460-B731-56A9D837A60DQ38297320-830E9A33-F121-41D0-BB25-E7F8C731E929Q38591066-47B31237-C3C1-4BAD-8184-DF9B3B0C8D31Q38849500-1E116BB7-72B5-40A7-A5E1-B5E4F119DAC7Q41915232-5B4DD444-C313-4492-AEF3-1458535F42C7Q42643973-AEA24A37-5C23-415F-A399-7C2D166113A8Q42756564-9A177C4B-8A8F-4B00-873C-3F2DCE8E76B3Q42759312-4C301A6C-AED1-41DC-A639-1862DF039211Q46040743-2F87F5B1-C79A-41FE-BD9B-F05F20CD8E13Q47134018-5CCB1C32-8E10-4FF1-995C-954455A63A95Q47189446-23AAEF0A-CB54-4308-9071-80F25D4EE9C1Q47554623-4DD9544F-17A4-415E-AF5F-5E8129013DDCQ50900158-22102E2D-DF3D-4DE3-BE4F-ADD6C7D87770Q51854381-413BD3FE-A252-4AC8-83BF-FBF0AC7F4AF6Q53125747-CD9534AB-4793-4E56-930D-1F2586D9F70AQ53130326-BBE0A967-6A9A-44C8-83B9-A0043A4B7CCDQ53387942-917AB3A1-E55C-4F45-A57C-72169104A5AAQ53766709-F619BDFC-197A-4C1F-85FA-BA40E6AFBCC0Q54855158-3D62F456-495E-4A13-99AD-1AC7EEFB58B3Q58127248-17C0A721-3419-4B24-8FBE-A7F1C34D7F0BQ58700723-4E9B1180-8972-46DB-AB6A-ABEAF6F54513Q58771367-580A1B1D-0569-42F6-B409-872CF9F51EFC
P2860
Tumor markers in clinical practice: a review focusing on common solid cancers
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tumor markers in clinical practice: a review focusing on common solid cancers
@en
type
label
Tumor markers in clinical practice: a review focusing on common solid cancers
@en
prefLabel
Tumor markers in clinical practice: a review focusing on common solid cancers
@en
P2860
P356
P1476
Tumor markers in clinical practice: a review focusing on common solid cancers
@en
P2093
Michael J Duffy
P2860
P356
10.1159/000338393
P5008
P577
2012-05-15T00:00:00Z